Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Kuepfer, Lars, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Lippert, Joerg
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081290/
https://www.ncbi.nlm.nih.gov/pubmed/21526168
http://dx.doi.org/10.1371/journal.pone.0017626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081290/
https://www.ncbi.nlm.nih.gov/pubmed/21526168
http://dx.doi.org/10.1371/journal.pone.0017626

Ejemplares similares